Products
Produvofusp Biosimilar Nanobody Fusion Protein for Research
Cat No.: GMP-Bios-INN-1348
Anti-TBC therapeutic antibody (Pre-made Produvofusp biosimilar,Nanobody Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Produvofusp is a nanobody fusion protein comprising the catalytic domain (residues 1-305) of human complement factor H fused to a humanized single-domain (VHH) immunoglobulin fragment. It acts as a complement factor H modulator. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1348-1mg | 1mg | 3090 |
| GMP-Bios-INN-1348-10mg | 10mg | |
| GMP-Bios-INN-1348-100mg | 100mg | |
| GMP-Bios-INN-1348-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Produvofusp biosimilar, Nanobody Fusion Protein: Recombinant therapeutic protein targeting TBC |
| INN Name | Produvofusp |
| Target | TBC |
| Format | Nanobody Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na |
| VD LC | na |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
